Teaser text

The 2017 global definition of dry eye disease—a common, yet poorly managed condition that is prevalent in up to 50% of Asian populations—highlights the importance of loss of tear film homeostasis and neurosensory abnormalities. This research program has developed and validated a suite of techniques and instruments which focus on these two key disease processes.

Body Text

Competitive advantage

  • Extensive and long-standing clinical and laboratory-based experience in dry eye disease
  • Comprehensive suite of technologies not available elsewhere in Australia
  • Diverse and well-established database of potential study participants. Specialty clinics facilitate targeted patient recruitment (Dry Eye, Red Eye, Contact Lenses, Myopia Control)


  • Dry eye affects over 4 million Australian women. It is associated with reduced productivity at work, reduced subjective quality of life, equivalent to severe angina, and a significant and ongoing Medicare burden. Improved diagnostics, particularly those that target the key pathophysiological mechanisms, will enable more appropriate treatment and monitoring of the impact of treatment.

Successful outcomes

  • Established track record of clinical studies – Phase 1, first in man – Phase 4 trials.

Capabilities and facilities

  • Measuring sensitivity
  • Subjective symptomatology
  • In vivo confocal microscopy
  • Tear neuropeptides and tear homeostasis

Our partners

  • Alcon
  • Allergan
  • Bausch + Lomb
  • CooperVision
  • Johnson and Johnson Vision Care
  • Novartis
  • Stiltec
  • Menicon
  • Azura